Advisers Royalty Pharma

HENRY GOSEBRUCH
JP MORGAN CAZENOVE MANAGING DIRECTOR

JP Morgan Cazenove is advising Royalty Pharma on its proposed purchase of Elan, led by Henry Gosebruch, who is a managing director in the firm’s mergers and acquisition group. Gosebruch’s focus is on the pharmaceutical and industrial sectors and he has worked on M&A transactions worth over $100bn (£66bn). Notable deals include Sanofi-Aventis’s unsolicited acquisition of Genzyme for $20bn, Merck’s acquisition of Schering-Plough for $41bn and ImClone’s sale to Eli Lilly for $6.5bn.

He is joined by Dwayne Lysaght, JP Morgan Cazenove’s head of UK mergers and acquisitions, who recently helped to complete Cable and Wireless Communications’ $750m deal to sell its interests in Macau to Citic. Other deals include Cambridge microchip firm CSR’s $310m sale of its mobile technology division to Samsung, News Corp’s aborted bid for BSkyB and the sale of Dairy Crest’s French spreads business for around £350m.

Also on the team is James Mitford, a director in M&A, who worked on the Dairy Crest deal as well as the offer for Proximagen Group by USL Pharma.

Bank of America Merrill Lynch and Groton Partners are acting as co-advisers to Royalty Pharma. By Victoria Scholar